Research is expanding rapidly. Promising areas include: NAFLD/NASH (fatty liver disease—semaglutide showed significant improvement in liver fibrosis), PCOS (weight loss improves insulin resistance and ovulation), cardiovascular risk reduction (proven in SELECT trial), sleep apnea (weight loss reduces severity), and addiction (early studies suggest GLP-1s may reduce cravings for alcohol, nicotine, and other substances). Kidney disease protection is also being studied. Most of these uses are off-label but supported by growing evidence. This is one of the most exciting areas of GLP-1 research.